Bristol-Myers Squibb And Pfizer Announce New Data On Stroke Prevention In Atrial Fibrillation To Be Presented At American Heart Association 2012 Scientific Sessions

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that a large number of data presentations sponsored by the companies on ELIQUIS ® (apixaban) and the treatment of atrial fibrillation will be presented at the American Heart Association 2012 Scientific Sessions, November 3-7, 2012, in Los Angeles, California. Among the presentations are two prespecified subanalyses from the ARISTOTLE trial: a more detailed analysis of ISTH major bleeding with ELIQUIS versus warfarin and an evaluation of the safety and efficacy of ELIQUIS versus warfarin in patients with prior warfarin experience (warfarin-experienced compared with warfarin-naïve). Also being presented is a subanalysis from ARISTOTLE of the safety and efficacy of ELIQUIS versus warfarin in patients with prior coronary artery disease. The ARISTOTLE trial evaluated the efficacy and safety of ELIQUIS, an investigational compound for the prevention of stroke or systemic embolism, in patients with nonvalvular atrial fibrillation compared with warfarin.

Company-sponsored real-world data analyses providing relevant insights on management of atrial fibrillation and experience with warfarin, such as the correlation between bleeding and discontinuation, warfarin outcomes in the real-world compared to trial data, and early ischemic outcomes after warfarin initiation will also be presented.

Details on the ARISTOTLE data analyses and real-world data analyses at the congress are as follows:
 
ARISTOTLE SUBANALYSES
Session Details   Presentation Title   Lead Author
Monday

November 5, 2012

10:45–11:00 PST

Abstract Oral Session

Room 403a
  Apixaban in Patients with Atrial Fibrillation and Prior Coronary Artery Disease: Insights from the ARISTOTLE Trial   Maria Cecilia Bahit, MD, ECLA, Rosario, Argentina
Monday

November 5, 2012

11:15-11:30 PST

Abstract Oral Session

Hall A-10
  Apixaban versus Warfarin in Patients with Atrial Fibrillation in Relation to Prior Warfarin Use: Insights from the ARISTOTLE Trial   David A. Garcia, MD, University of New Mexico, Albuquerque, NM
Tuesday

November 6, 2012

3:00–4:30 PST

Abstract Poster Session

Kentia Hall, Core 2, Poster Board: 2068
  Reduction in Bleeding with Apixaban versus Warfarin is Consistent Across Subgroups and Locations: Insights from the ARISTOTLE Trial   Elaine M. Hylek, MD, Boston University, Boston, MA
OUTCOMES RESEARCH/REAL-WORLD DATA
Session Details   Presentation Title   Lead Author
Sunday

November 4, 2012

9:30–11:00 PST

Abstract Poster Session

Kentia Hall, Core 2, Poster Board: 2117
  Post-Discharge Stroke in Patients With Atrial Fibrillation: A Follow-Up Study in Major Cities of China   Bao Liu, Ph.D., School of Public Health, Fudan University, Shanghai, China
Sunday

November 4, 2012

3:00–4:30 PST

Abstract Poster Session

Kentia Hall, Core 2, Poster Board: 2094
  The Association Between Bleeding and Warfarin Discontinuation in Patients with Atrial Fibrillation   Xianying Pan, Bristol-Myers Squibb, Wallingford, CT
Monday

November 5, 2012

9:30–11:00 PST

Best of AHA Specialty Conferences
  Exposure to Warfarin and the Risks of Stroke and Bleeding Events among Patients with Non-Valvular Atrial Fibrillation: Real-World vs. Clinical Trial   Alpesh Amin, MD, University of California, Irvine, Irvine, CA
Tuesday

November 6, 2012

9:30–11:00 PST

Abstract Poster Session

Kentia Hall, Core 2, Poster Board: 2176
  Impact of Bleeding on Length of Stay and Total Cost in Atrial Fibrillation Patients   Alpesh Amin, MD, University of California, Irvine, Irvine, CA
Tuesday

November 6, 2012

9:30–11:00 PST

Abstract Poster Session

Kentia Hall, Core 2, Poster Board: 2177
  Evaluation of Patient-Reported Disease Burden of Atrial Fibrillation   Liu Xianchen, Pfizer Inc., New York, NY
Tuesday

November 6, 2012

9:30–11:00 PST

Abstract Poster Session

Kentia Hall, Core 2, Poster Board: 2175
  Utilization Patterns of Anticoagulants in Non-Valvular Atrial Fibrillation after the entry of Novel Oral Anticoagulants in the United States   Melissa Hamilton, MPH, Bristol-Myers Squibb, Princeton, NJ
Wednesday

November 7, 2012

9:15–9:30 PST

Abstract Oral Session

Room 511
  Early Effects on Ischemic Strokes After Initiation of Warfarin in Patients With Atrial Fibrillation   Laurent Azoulay, Ph.D., M.Sc., Jewish General Hospital, Montreal, Canada
Wednesday

November 7, 2012

9:30–11:30 PST

Abstract Poster Session

Kentia Hall, Core 2, Poster Board: 2051
  Tolerability of Apixaban — Insights From A Meta-Analysis of Discontinuation Rates in Randomized Trials   Ria Kundu, MD, University of Toledo, Toledo, OH

About Atrial Fibrillation

Atrial fibrillation is the most common cardiac arrhythmia (irregular heart beat). It is estimated that more than 5.8 million Americans and 6 million individuals in Europe have atrial fibrillation. The lifetime risk of developing atrial fibrillation is estimated to be approximately 25 percent for individuals 40 years of age or older. One of the most serious medical concerns for individuals with atrial fibrillation is the increased risk of stroke, which is five times higher in people with atrial fibrillation than those without atrial fibrillation. In fact, 15 percent of all strokes are attributable to atrial fibrillation in the U.S. Additionally, strokes due to atrial fibrillation are more burdensome than strokes due to other causes. Atrial fibrillation-related strokes are more severe than other strokes with an associated 30-day mortality of 24 percent and a 50 percent likelihood of death within one year in patients who are not treated with an antithrombotic.

If you liked this article you might like

Bristol-Myers Squibb Stock Still a Beast?

There Are Good Opportunities in Stock Picking

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Achillion Shares Are Plunging on Termination of Hepatitis C Pact